Kolexia
Kuhnowski Frederique Hématologie
Kuhnowski Frederique
Hématologie
Clcc Institut Curie
Paris, France
76 Activités
132 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Myélome multiple Lymphomes Tumeurs à plasmocytes Lymphome B Tuberculose Maladie veno-occlusive hépatique Tumeurs du sein Lymphome B diffus à grandes cellules Maladie de Hodgkin

Collaborateurs

Voir plus
Belhadj-Merzoug Karim
Belhadj-Merzoug Karim
Hôpital Henri Mondor, Créteil, France
Bedoui Manel
Bedoui Manel
Clcc Institut Curie, Paris, France
Garderet Laurent
Garderet Laurent
Hôpital Pitie Salpetriere, Paris, France
Karlin Lionel
Karlin Lionel
Hôpital Lyon Sud, Pierre-Bénite, France

Industries

Voir plus
A+A
26 collaboration(s)
Dernière en 2023
Janssen
26 collaboration(s)
Dernière en 2023
Sanofi
18 collaboration(s)
Dernière en 2023
Amgen
16 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
POSTER: MM-158 A Challenging Diagnosis of a Patients With Synchronous Multiple Myeloma and Breast Cancer: A Case Report
Proceedings of the Society of Hematologic Oncology 2023 Annual Meeting   01 septembre 2023
MM-158 A Challenging Diagnosis of a Patients With Synchronous Multiple Myeloma and Breast Cancer: A Case Report
Proceedings of the Society of Hematologic Oncology 2023 Annual Meeting   01 septembre 2023
PCD: A Multicenter Open Label Phase II Study of Pomalidomide and Cyclophosphamide and Dexamethasone in Relapse/Refractory Multiple Myeloma Patients Who Were First Treated Within the IFM/DFCI 2009 Trial
Essai Clinique (Celgene)   03 juillet 2023
Pomalidomide and dexamethasone until progression after first salvage therapy in multiple myeloma.
British journal of haematology   27 mars 2023
Phase II Study of the Combination of Pomalidomide with Dexamethasone As Maintenance Therapy after First Relapse Treatment with PCD Followed or Not By Autologous Stem Cell Transplant in Multiple Myeloma Patients
Blood   23 novembre 2021
Carfilzomib maintenance in newly diagnosed non-transplant eligible multiple myeloma.
Leukemia   14 octobre 2021
Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial.
The Lancet. Oncology   13 septembre 2021
Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab + bortezomib/thalidomide/dexamethasone in the phase 3 CASSIOPEIA study.
Haematologica   01 août 2021
Cassiopeia: Study of Daratumumab in Combination With Bortezomib (VELCADE), Thalidomide, and Dexamethasone (VTD) in the First Line Treatment of Transplant Eligible Subjects With Newly Diagnosed Multiple Myeloma
Essai Clinique (Intergroupe Francophone du Myélome)   03 décembre 2020
Hodkgin lymphoma concomitant of tuberculosis, a therapeutic challenge for multidisciplinary management.
Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique   19 mai 2020